Home Venture Capital Unlearn Raises $50M in Series C Funding

Unlearn Raises $50M in Series C Funding

13
0
Unlearn

Unlearn

Unlearn, a San Francisco, CA-based AI company creating digital twins of clinical trial participants that enable research, raised $50M in Series C funding.

The round was led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital.

The company intends to use the funds to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering capabilities, and longer-term R&D initiatives.

Led by Charles Fisher, Ph.D., Founder and CEO, Unlearn is a technology company advancing AI to eliminate trial and error in medicine. Its technology empowers the clinical trials of global pharmaceutical companies, helping them to reach full enrollment faster and bring new treatments to patients sooner.

Unlearn’s AI models generate an individual digital twin for every trial participant before they are randomized into the experimental or control arm. The participant’s digital twin forecasts their health outcomes under placebo, regardless of their actual assignment. Digital twins enable TwinRCTs,TM highly powered clinical trials with smaller control groups, allowing more patients to receive experimental treatment. TwinRCTs reduce the time it takes to bring new drugs and therapies to market, ultimately paving the way for improved health outcomes for all.

Their methods using participants’ digital twins are qualified by the European Medicines Agency and align with current FDA guidance.

Commenting on the news, Charles Fisher said: “Breaking down these barriers and proving the value of digital twin technology continues to be a main driver for us at Unlearn. And, this round of financing will allow us to not only grow our team but also expand our capabilities into more therapeutic areas to build awareness and prove the value.”

FinSMEs

08/02/2024

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here